CaSR antagonist

Details CaSR antagonist CaSR antagonist

2007-10-23

2007-10-23

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S557000, C514S567000, C514S576000, C562S400000, C564S305000

Reexamination Certificate

active

11286378

ABSTRACT:
The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof:wherein each symbol is as defined in the description.

REFERENCES:
patent: 6022894 (2000-02-01), Del Mar et al.
patent: 6291459 (2001-09-01), Bhatnagar
patent: 6294531 (2001-09-01), Barmore et al.
patent: 6335338 (2002-01-01), Bhatnagar
patent: 6395919 (2002-05-01), Bhatnagar
patent: 6417215 (2002-07-01), Lago
patent: 6916956 (2005-07-01), Shinagawa et al.
patent: 901459 (1999-03-01), None
patent: 973730 (2000-01-01), None
patent: 1070048 (2001-01-01), None
patent: 2001-501584 (2001-02-01), None
patent: 2001-523223 (2001-11-01), None
patent: 2002-510671 (2002-04-01), None
patent: 2002-522499 (2002-07-01), None
patent: 2002-522532 (2002-07-01), None
patent: 2002-536330 (2002-10-01), None
patent: 97/37967 (1997-10-01), None
patent: 98/45255 (1998-10-01), None
patent: 99/51241 (1999-10-01), None
patent: 99/51569 (1999-10-01), None
patent: 00/09132 (2000-02-01), None
patent: 00/09491 (2000-02-01), None
patent: 00/45816 (2000-08-01), None
patent: 02/07673 (2002-01-01), None
patent: 02/14259 (2002-02-01), None
patent: 02/34204 (2002-05-01), None
patent: 02/38106 (2002-05-01), None
Co-pending U.S. Appl. No. 10/830,480.
C.S. Tam, et al., Parathyroid Hormone Stimulates the Bone Apposition Rate Independently of its Resorptive Action: Differential Effects of Intermittent and Continuous Administration,Endocrinology, 110, 506-512 (1982).
T. Uzawa, et al., Comparison of the Effects of Intermittent and Continuous Administration of Human Parathyroid Hormone (1-34) on Rat Bone,Bone, 16, 477-484 (1995).
A. Scott, et al., Time Dependent Effects of Parathyroid Hormone and Prostaglandin E2 on DNA Synthesis by Periosteal Cells from Embryonic ChickCalvaria, Calcified Tissue International, 55, 208-215 (1994).
T.J. Wronski, et al., Parathyroid Hormone is More Effective Than Estrogen or Bisphosphonates for Restoration of Lost Bone Mass in Ovariectomized Rats,Endocrinology, 132, 823-831 (1993).
T. J. Wronski, et al., Anabolic effects of parathyroid hormone on cortical bone in ovari-ectomized rates,Bone, 15, 51-58 (1994).
L. Mosekilde, et al., The Anabolic Effects of Human Parathyroid Hormone (hPTH) on Rat Vertebral Body Mass Are also Reflected in the Quality of Bone, Assessed by Biomechanical Testing: A Comparison Study between hPTH-1(1-34) and hPTH(1-84),Endocrinology, 129, 421-428 (1991).
E.M. Brown, et al., Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid,Nature, 366, 575-580 (1993).
T.M. Gowen, et al., Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats,The Journal of Clinical Investigation, vol. 105, pp. 1595-1604 (2000).
C. Ejersted, et al., Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats,Journal of Bone and Mineral Research, 8, 1097-1101 (1993).

Affiliated with

Also associated with

Rating

CaSR antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CaSR antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CaSR antagonist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3869281